L-PRF versus connective tissue graft with a customized healing abutment for immediate single-tooth implants

Evaluation of Soft and Hard Tissue Augmentation by Connective Tissue Graft or Leukocyte-Platelet Rich Fibrin in Immediate Implant Placement With Customized Healing Abutment: A Randomized Controlled Clinical Trial.

Not applicable Interventional Kafrelsheikh University · NCT07102758

This will test whether using L-PRF or a connective tissue graft together with a customized healing abutment gives better soft- and hard-tissue outcomes for people receiving immediate single-tooth implants in the upper jaw.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment16 (estimated)
Ages21 Years to 45 Years
SexAll
SponsorKafrelsheikh University Academic / other
Drugs / interventionschemotherapy
Locations1 site (Kafr ash Shaykh, Kafrelsheikh)
Trial IDNCT07102758 on ClinicalTrials.gov

What this trial studies

This interventional comparison enrolls patients receiving immediate implants for non-restorable single-rooted maxillary centrals, canines, or premolars and treats the site with either L-PRF or an autologous connective tissue graft plus a customized healing abutment. Participants must have an intact labial/buccal bone plate, sufficient bone volume and width confirmed by CBCT, good oral hygiene, and be nonsmokers. Soft-tissue and hard-tissue outcomes such as gingival recession, soft-tissue thickness, and peri-implant bone levels will be recorded over follow-up visits using clinical measurements and imaging. The protocol excludes patients with insufficient bone, active infection, systemic diseases, pregnancy, or current cancer therapy.

Who should consider this trial

Good fit: Ideal candidates are nonsmoking adults with a single non-restorable maxillary central, canine, or premolar, an intact buccal bone plate and at least 1 mm of buccal bone width as confirmed by CBCT.

Not a fit: Patients with insufficient bone volume, active infection, uncontrolled systemic disease, ongoing chemotherapy or radiotherapy, pregnancy, bone disorders, periapical pathology, or smokers are unlikely to benefit from this protocol.

Why it matters

Potential benefit: If successful, the preferred approach could improve soft tissue coverage and preserve buccal bone around immediate implants, enhancing esthetic outcomes and long-term implant stability.

How similar studies have performed: Previous clinical reports and small trials have shown promising but variable results for L-PRF and connective tissue grafting in immediate implant sites, so this comparison builds on existing but not definitive evidence.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Intact labial/buccal bone plate
* The presence of non-restorable single-rooted maxillary centrals, canines or premolars.
* Sufficient bone volume.
* Good oral hygiene.
* Nonsmokers.
* Sufficient bone width (≥ 1 mm) in the buccal plate of the remaining bone to place an implant confirmed by cone beam computer tomography (CBCT).

Exclusion Criteria:

* Insufficient bone volume.
* Active infection.
* Patients on chemotherapy or radiotherapy.
* Patients who have systemic disorders {uncontrolled diabetes mellitus, autoimmune disease, …etc},
* Pregnant patients,
* Patients with bone diseases
* Presence of periapical pathology.

Where this trial is running

Kafr ash Shaykh, Kafrelsheikh

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Recession, GingivalBone Loss in JawL-prfconnective tissuecustomized healing abutmentimplant
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.